Obliterative bronchiolitis – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:37:26 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Obliterative bronchiolitis – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Long-Term Safety and Effectiveness of Liposomal Ciclosporin A for Patients with Bronchiolitis Obliterans Syndrome After Lung Transplantation https://clinicaltrials.eu/trial/study-on-long-term-safety-and-effectiveness-of-liposomal-ciclosporin-a-for-patients-with-bronchiolitis-obliterans-syndrome-after-lung-transplantation/ Wed, 29 Apr 2026 15:01:26 +0000 https://clinicaltrials.eu/trial/study-on-long-term-safety-and-effectiveness-of-liposomal-ciclosporin-a-for-patients-with-bronchiolitis-obliterans-syndrome-after-lung-transplantation/ This clinical trial is focused on studying a condition called Bronchiolitis Obliterans Syndrome (BOS), which can occur in patients who have received a single or double lung transplant. The study is investigating the long-term safety and effectiveness of a treatment called Liposomal Ciclosporin A (L-CsA). This treatment is administered as a powder for nebulizer solution, which means it is inhaled through a device that turns the medication into a mist.

The purpose of the study is to assess how well L-CsA works and how safe it is for patients with BOS. Participants in the study will receive L-CsA in addition to their standard care, which may include medications like tacrolimus, mycophenolate mofetil (MMF), azathioprine, and prednisone. Some patients may also receive azithromycin for additional support. The study will monitor various health indicators, such as lung function and overall health, over a period of time to determine the treatment’s impact.

Throughout the study, participants will be regularly assessed to track any changes in their condition and to ensure their safety. The study aims to provide valuable information on the potential benefits and risks of using L-CsA for treating BOS in lung transplant recipients. This research is part of a follow-up to previous studies known as BOSTON 1 and BOSTON 2, which also explored the use of L-CsA in similar patient groups.

]]>